10x Genomics Financials - Benzinga

10x Genomics Inc

TXGNASDAQ

Trade with Public

Trade with Public

$64.16

-0.56-0.87%

마지막 업데이트: Aug 26, 9:13 AM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

10x Genomics Financials

10x Genomics (TXG) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est

10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $600.000 million-$625.000 million to $610.000 million-$630.000 million vs $613.851 million estimate.

Benzinga Newsdesk

PRO
10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 150 percent decrease over earnings of $0.28 per share from the

Benzinga Newsdesk

PRO
10x Genomics Affirms FY2026 Sales Guidance of $600.000M-$625.000M vs $613.107M Est.

10x Genomics (NASDAQ:TXG) affirms FY2026 sales outlook from $600.000 million-$625.000 million to $600.000 million-$625.000 million vs $613.107 million estimate.

Benzinga Newsdesk

PRO
10x Genomics Q1 EPS $(0.10) Beats $(0.30) Estimate, Sales $150.843M Beat $146.355M Estimate.

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.30) by 66.67 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

Earnings Scheduled For February 18, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved